Investment
Features
FeesSafety
Academy
More
Pluang+

Bitcoin could hit $100,000 by end of 2026, says Galaxy Digital CEO Mike Novogratz.

Market News
28 Sep 2026
Tokenpost
View Source
Bullish
Bitcoin could hit $100,000 by end of 2026, says Galaxy Digital CEO Mike Novogratz.

Galaxy Digital CEO Mike Novogratz expressed his personal view that Bitcoin might reach $100,000 by the end of 2026, citing positive trends in the crypto market and Bitcoin's chart. He noted that capital could shift between high-momentum stocks and crypto assets depending on market conditions. This outlook aligns with a technical analysis from Fidelity's Jurrien Timmer, who sees a conditional $100,000 target if Bitcoin surpasses resistance near $80,000. Novogratz's prediction is not a company forecast or guarantee, but highlights growing optimism in Bitcoin's potential price movement.

The story on Bitcoin price outlook is provided here with Pluang's market data for context. For readers following cryptocurrency, as of Sep 29, 2026 02:51 WIB, out of 50 major cryptocurrencies on Pluang, 10 rose and 39 fell today. Notable movers include AXS at Rp19.786 with a 1-day change of -7.22%, SUSHI at Rp4.488 down 7.19%, and GRT at Rp540 down 7.17%.

More News

RGA stock set for 16.7% rise on strong earnings and favorable market conditions

RGA stock set for 16.7% rise on strong earnings and favorable market conditions

Morgan Stanley raised the price target for Reinsurance Group of America (RGA) to $295, implying a 16.7% upside from its current price of $252.85. The company reported a 42% increase in adjusted operating income to $746 million in H1, driven by its lo...

Analyst Insights
Bullish
1 hour ago
Mirum Pharmaceuticals' price target raised to $195 after key drug approvals and trial success

Mirum Pharmaceuticals' price target raised to $195 after key drug approvals and trial success

H.C. Wainwright raised Mirum Pharmaceuticals' price target from $140 to $195 following positive developments: the Phase 3 AZURE-1 trial for Brelovitug met its main goal for treating Chronic Hepatitis Delta Virus, and the FDA approved Atebrioz™ for Fi...

Analyst Insights
Bullish
2 hours ago
Kodiak Sciences stock jumps 176% after positive Phase 3 trial for retinal disease drug

Kodiak Sciences stock jumps 176% after positive Phase 3 trial for retinal disease drug

Kodiak Sciences reported successful Phase 3 trial results for its retinal disease treatments Zenkuda and tabirafusp-ted, showing vision improvements comparable to Regeneron's Eylea. Zenkuda allowed 54% of patients to maintain a six-month dosing inter...

Market News
Bullish
2 hours ago
Citigroup keeps Neutral on Regeneron amid rising competition from Kodiak Sciences' eye drug success

Citigroup keeps Neutral on Regeneron amid rising competition from Kodiak Sciences' eye drug success

Citigroup has maintained a Neutral rating on Regeneron Pharmaceuticals due to increasing competition in the ophthalmology sector. Kodiak Sciences reported positive Phase 3 trial results for its eye drugs, challenging Regeneron's key product, Eylea, e...

Analyst Insights
Neutral
3 hours ago
Bittensor proposes Gamma tokens to enable subnet collaboration via emission-backed credits

Bittensor proposes Gamma tokens to enable subnet collaboration via emission-backed credits

Bittensor has introduced a proposal for Gamma tokens, a new economic layer allowing its subnets to trade compute and inference services using credits backed by their own TAO emissions. This shifts TAO from being solely a reward token to also serving ...

Protocol Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App